Advanced Filter

Filter by Group

Filter by Market Availability

Displaying drugs 14226 - 14250 of 15221 in total
Rexin-G is a tumor-targeted, injectable retroviral vector carrying a mutant form of the cyclin G1 gene. It is under development by Epeius Biotechnologies for the potential treatment of metastatic cancer. It is also being investigated for preventing SARSCOV-2 viral entry.
Investigational
Experimental
Experimental
Experimental
Experimental
Botensilimab is under investigation in clinical trial NCT03860272 (Fc-engineered Anti-ctla-4 Monoclonal Antibody in Advanced Cancer).
Investigational
Etokimab is under investigation in clinical trial NCT03614923 (Etokimab in Adult Patients With Chronic Rhinosinusitis With Nasal Polyps (Crswnp)).
Investigational
Pimivalimab is under investigation in clinical trial NCT04549025 (Study of PD-1 Inhibitor JTX-4014 Alone and in Combination With Vopratelimab in Biomarker-selected Subjects With Metastatic NSCLC After One Prior Platinum-containing Regimen).
Investigational
Matched Description: … Pimivalimab is under investigation in clinical trial NCT04549025 (Study of PD-1 Inhibitor JTX-4014 Alone and
Mibavademab is under investigation in clinical trial NCT04159415 (Study of REGN4461, a Leptin Receptor Agonist Antibody, in Patients With Generalized Lipodystrophy).
Investigational
Nadecnemab is under investigation in clinical trial NCT03956550 (A Study to Examine the Efficacy and Safety of REGN5069 in Patients With Pain Due to Osteoarthritis of the Knee).
Investigational
Matched Description: … Nadecnemab is under investigation in clinical trial NCT03956550 (A Study to Examine the Efficacy and
Favezelimab is under investigation in clinical trial NCT04626479 (Substudy 03A: A Study of Immune and Targeted Combination Therapies in Participants With First Line (1L) Renal Cell Carcinoma (MK-3475-03A)).
Investigational
Matched Description: … Favezelimab is under investigation in clinical trial NCT04626479 (Substudy 03A: A Study of Immune and
Investigational
Investigational
Adlinacogene civaparvovec is an investigational in vivo genome editing therapeutic product. It uses proprietary zinc finger nuclease (ZFN) genome editing to insert into the DNA of liver cells a copy of the F9 gene, which controls the production of Factor IX. Developed by Sangamo Therapeutics Inc., it is being investigated...
Experimental
Devafidugene civaparvovec is an investigational in vivo genome editing product. It uses proprietary zinc finger nucleases (ZFN) that insert a functional copy of the alpha-L-iduronidase (IDUA) enzyme. Developed by Sangamo Therapeutics, Inc., devafidugene civaparvovec is being investigated for the treatment of mucopolysaccharidosis Type I (MPS I).
Experimental
Displaying drugs 14226 - 14250 of 15221 in total